Boston Scientific's Public Offering: Prelude to Deals?
Executive Summary
After Boston Scientific's successful public offering, Boston's stock price was up $46.50 on July 16, 1999, suggesting investors are growing confident that Boston Scientific can rejoin the ranks as one of the leading big-cap device companies in terms of earnings and growth. For non-investors, the public offering raises another question: will Boston Scientific also return to form as one of the device industry's most aggressive acquirers of other companies?
You may also be interested in...
Thermo Fisher Scientific, Hillrom To Acquire Diagnostics Companies To Bolster Portfolios
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Cosmetic And Personal Care Trademark Review 19 January, 2021
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
CMS Extends National Medicare Coverage For Transcatheter Mitral Valve Repair
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.
Need a specific report? 1000+ reports available
Buy Reports